Tyrosine kinase inhibitorFDA-approvedSecond-line
Tafinlar + Mekinist
Generic name: dabrafenib + trametinib
How it works
Blocks the activity of proteins called BRAF and MEK, which are involved in the growth and spread of cancer cells.
Cancer types
Melanoma— BRAF V600E-positive
Lung Cancer— BRAF V600E-mutated
Efficacy
In clinical trials, around 50% of BRAF-mutated patients achieved an objective response, with median progression-free survival of approximately 10 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.